Fluidigm combatendo Covid-19
Fluidigm combatendo Covid-19 com sua tecnologia de microfluidica
Fluidigm is teaming with a growing body of researchers around the world who are working to mount an aggressive and sustainable response to the COVID-19 pandemic. We are actively engaged on multiple fronts: We believe our microfluidics and mass cytometry capabilities are critical for virus detection and immune profiling of individuals, and they will be increasingly important to government and medical institutions. We are engaged with and providing support to our customers and the global research community in this fight. A consortium of medical schools with support from DARPA is utilizing our technology to develop an epigenetic test for early detection of the novel coronavirus that causes COVID-19. Our microfluidics technology is ideally suited to the task. The consortium plans to seek Emergency Use Authorization for its COVID-19 test from the U.S. Food and Drug Administration. We believe that supporting other developers and labs seeking authorization for tests employing our unique integrated fluidic circuit (IFC) technology has the potential to add significant testing capacity. Quick and reliable detection is crucial. In addition to the aforementioned epigenetics-based approach, we support ultrahigh-throughput sample processing of RNA-based virus detection via the same microfluidics platforms. New and valuable COVID-19 research is emerging, aided by our technology. For example, groundbreaking work led by a Chinese team in global collaboration with other researchers in Asia, the United States and Europe used Fluidigm mass cytometry technology for patient immune profiling before and after stem cell transplants for severe COVID-19 pneumonia patients. The study suggests that mesenchymal stem cells could cure or significantly improve the functional outcomes of these patients without observed adverse effects. Broad-based immune profiling. Numerous organizations around the world are exploring immune profiling of the COVID-19 infected population. We are offering our Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ analysis software as a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers. We can develop alternative or novel panels as well. Please contact us immediately if we can help you submit proposals or fulfill recently awarded programs. Our products, technologies and expertise enable global research on multiple frontiers of human health. We continue this work while ensuring that our employees are safe, our customers are supported and our supply chain remains strong. The response to the COVID-19 pandemic requires transformative technology, decisive action and world-class expertise. We will continually adapt our capabilities to the evolving situation and keep you informed as we all work to develop and deploy solutions that have a meaningful impact.
Chris Linthwaite President and CEO